Legislation & Regulatory Updates
AST is your voice and seat at the table on Capitol Hill, within the Executive Branch, Federal Agencies and in many state capitols and legislatures. These governmental agencies dictate and have direct oversight of most aspects of transplant patient care and medical research. From clinical to research, the field of organ transplantation is heavily regulated and frequently addressed by both our elected and un-elected federal and state leaders.
AST maintains a strong bipartisan and bicameral presence to educate, cultivate and mobilize support for the Society's public policy agenda. Members of Congress, their staff and senior HHS officials know the Society well and work with its members and the Washington, DC, government relations staff on a daily basis.
Twice a year, the Organ Procurement and Transplant Network (OPTN) releases proposed new policy for public comment (http://optn.transplant.hrsa.gov/governance/public-comment/). Members of the transplant community and the interested public are encouraged to provide feedback on the proposals. As part of its larger advocacy goals, the American Society of Transplantation reviews the policies and provides feedback, where appropriate. The Society seeks input from key constituencies to inform our commentary as follows:
1. The AST OPTN/UNOS Policy Committee and AST President review each proposed policy released for comment to assess which Communities of Practice or Committees should review the proposals and suggest comments.
2. The leadership of the appropriate Communities of Practice or Committees develop suggested comments that they forward to the AST OPTN/UNOS Policy Work Group.
3. The AST OPTN/UNOS Policy Committee then reviews all of the comments and generates a single comment for each policy that clearly states the position of the Society as being in favor, as having specific concerns, or opposing the proposed policy.
4. The AST Board of Directors then meets with the AST OPTN/UNOS Board Liaison to approve or amend the comments that are submitted to the OPTN on the proposed policies.
AST comments on OPTN/UNOS Policy Proposals:
- October 2, 2017 comments on 13 proposals
- March 25, 2017 special comment period on 1 proposal
- January 23, 2017 Comments on 6 proposals
- October 11, 2016: Comments on 15 proposals
- March 23, 2016: Comments on 9 proposals and one concept paper
AST Feedback on Pending Legislation
- The AST drafted a coalition letter regarding the issues of chronic care and pre-existing conditions as addressed in the current Repeal and Replace efforts ongoing in the US Senate. (September 2017)
- AST signed on to a coalition letter urging legislators to ensure that all members of the health care workforce with Deferred Action of Childhood Arrivals (DACA) status are able to continue their employment, education, training, and research, with passage of a permanent legislative remedy, such as the Dream Act of 2017 (September 2017)
- The Society signed on to a community letter expressing concerns regarding the FY2018 funding proposal for NIH, including drastic reductions to NIH support for facilities and administrative expenses. (August 2017)
- The AST signs a coalition letter of support for the Living Donor Protection Act (July 2017)
- AST signs joint letter noting concern related to Dialysis Patient Demonstration Act in addition to submitting our own letter on this topic (June 2017)
- The Living Organ Donor Protection Act of 2017 has been reintroduced by Congressman Jerrold Nadler and Congresswoman Jaime Herrera Beutler. (February 2017)
- AST signs joint letter regarding President Trump's immigration executive order. (February 2017)
- A letter noting concern related to the ESRD Integrated Care Act's negative impacty on kidney transplantation.
- Helping Hospitals Improve Patient Care Act of 2016 (H.R. 5273) endorsed by the AST
- Living Donor Protection Act of 2016 - coalition letter spearheaded by AST and signed by more than 25 other organizations in support of this legislation that will protect living organ donors from job loss and other discrimination
- Concerns regarding the MedPAC's suggestion to remove immunosuppressant medications from the category of "protected drug class" on Medicare Part C and D formularies
Other Regulatory Updates
- The AST's Transplant Administrators and Transplant Pharmacy Commmunities of Practices provided input on revised Interpretive Guidelines for the CMS Conditions of Participation for Transplant Centers (October 2017)
- The AST and AAKP sent a joint letter of concern regarding regional coverage changes for IVIg therapy for kidney recipients in June 2017.
- The AST comments on U.S. Senate Majority Party Leadership Release of Healthcare Reform Discussion-Draft in June 2017.
- AST signed on to a Friends of HRSA coalition letter, encouraging appropriate HHS funding in March 2017.
- The AST signed on to a coalition letter regarding impacts of hiring freeze on public health services in Feburary 2017.
- The AST signed on to a coalition letter in January 2017 noting concerns regarding delays in reimbursement for home infusion therapies that were inadvertently created as part of the 21st Century Cures Act.
- The AST comments on recently passed American Health Care Act (AHCA).
- The AST comments on proposed modifications to CMS Transplant Outcome Measures and Documentation Requirements released on July 14, 2016
- The AST comments on revised CMS Interpretive Guidelines for the Organ Transplant Conditions of Participation for Transplant Centers released on April 11, 2016. Additional comments and suggested language changes were shared with CMS on May 26, 2016.
- The AST response to the National Institute of Health (NIH) call for comment on proposed "Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV.
Public Health Service (PHS) Guidelines
AST has provided the following comments on the PHS Guideline for Reducing the Transmission of Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) through Organ Transplantation:
- Understanding OPTN/UNOS PHS Guideline: Effective Oct. 1, 2013, a new policy created to define PHS Guidelines, will allow members to use either the 1994 or 2013 version
- September 12, 2012 - Comments on most recent draft of the guideline
- June 15, 2012 - Letter to James Berger, Senior Advisor for Blood Policy, Re: Transplant Community Questions and PHS Revised Guidelines for Reducing HIV, HBV, and HCV through Organ Transplantation
- November 17, 2011 - Letter to the Honorable Thomas Frieden, MD, MHP, Director, Centers for Disease Control and Prevention, Re: Docket No. CDC-2011-0011
- August 23, 2011 - Letter to the Honorable Howard Koh, MD, MPH, Assistant Secretary for Health, Department of Health and Human Services from AST, ASTS, AOPO, and NATCO expressing concerns with the proposed PHS Guideline for Reducing HIV/HBV/HCV Transmission